Metformin Combination Therapy: When Is Another Medicine Needed?

Metformin is commonly used to help manage blood glucose levels in people with type 2 diabetes.

However, it may not always provide sufficient glucose control on its own.

Some people may therefore need another diabetes medicine alongside metformin, while others may benefit from combination treatment earlier in their care.

Combination therapy usually involves using two or more medicines that work in different ways. This can help people reach their individual blood glucose targets and may also address other health concerns, such as cardiovascular disease, heart failure, chronic kidney disease or excess body weight.

The choice of treatment depends on an individual’s HbA1c, medical history, kidney function, risk of hypoglycemia, personal preferences and other health factors.

This guide outlines when combination therapy using metformin may be considered, what classes of medication may be used by your doctor and what you should know as a patient.

Medical note: This article is for general educational purposes. Do not add, stop or change a diabetes medicine without advice from your prescribing healthcare professional.

Article Index

What Is Metformin Combination Therapy?
When Might Another Medicine Be Added to Metformin?
How Do Doctors Choose the Right Combination?
Common Medicines Used Alongside Metformin
What Is Metformin Triple Therapy?
Are Fixed-Dose Metformin Combinations an Option?
How Is Combination Therapy Started and Monitored?
Side Effects and Safety Considerations
Frequently Asked Questions
Key Takeaway
References

What Is Metformin Combination Therapy?

Metformin mainly helps to reduce the amount of glucose made in your liver. It can also increase how sensitive your body is to insulin. While it can be very effective for many people, type 2 diabetes can progress over time so your initial treatment plan may need to be changed.

An additional medicine may complement metformin by working through a different mechanism. Some drugs such as SGLT2 inhibitors will increase glucose excretion via the kidneys in the urine. Others such as GLP-1 receptor agonists will affect hormones that control blood glucose levels and appetite.

This can help some people reach their treatment goals.

For a basic explanation of metformin’s action, read our guide on how metformin tablets help lower blood sugar.

Combination treatment doesn’t necessarily mean you’ll need to take several medications. Treatment should be tailored to your individual requirements, potential benefits, risks and preferences.

When Might Another Medicine Be Added to Metformin?

Another medicine may be considered when metformin alone is not providing sufficient blood glucose control or when an additional medicine offers benefits for a person’s cardiovascular or kidney health.

There is no single HbA1c level or waiting period that applies to everyone. The 2026 American Diabetes Association (ADA) Standards of Care recommend considering initial combination therapy to help adults with type 2 diabetes reach their individualized glucose targets sooner. This may be particularly relevant when HbA1c is substantially above the person’s target.

Treatment recommendations can vary between countries. For example, the February 2026 NICE guideline in the United Kingdom recommends offering modified-release metformin together with an SGLT2 inhibitor as initial treatment for adults with type 2 diabetes and no relevant comorbidities.

This differs from some other national treatment approaches. Patients should follow the recommendations and prescribing guidance applicable in their country.

When blood glucose remains above target

If HbA1c remains above the person’s individualized target, a clinician may review the current treatment plan and consider whether another medicine is appropriate.

Before adding another medicine, the healthcare professional may review whether metformin is being taken as prescribed, whether the current dose is tolerated, and whether other factors are affecting blood glucose control.

When cardiovascular disease is present

For people with type 2 diabetes who have established cardiovascular disease or indicators of high cardiovascular risk, the ADA recommends including an SGLT2 inhibitor and/or a GLP-1 receptor agonist with demonstrated cardiovascular benefits in the treatment plan.

These medicines may be recommended for cardiovascular risk reduction even when the person’s HbA1c is already at target and whether or not they are taking metformin.

When heart failure is present

Some SGLT2 inhibitors have demonstrated benefits in people with heart failure, including reducing the risk of hospitalization for heart failure.

A healthcare professional may consider one of these medicines as part of the treatment plan, taking kidney function, other medicines and individual circumstances into account.

When chronic kidney disease is present

For people with type 2 diabetes and chronic kidney disease, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated kidney and cardiovascular benefits may be recommended. The choice depends on kidney function, albuminuria, other health conditions and the specific medicine being considered.

Metformin use also depends on kidney function. Estimated glomerular filtration rate (eGFR) should be assessed before treatment and monitored periodically, as reduced kidney function may affect whether metformin is suitable and what dose can be used.

Treatment decisions are not based on HbA1c alone. A healthcare professional also considers overall health, kidney function, cardiovascular risk and the potential benefits and limitations of individual medicines.

How Do Doctors Choose the Right Combination?

There is no single best combination for individuals with type 2 diabetes.

A clinician will consider the following factors.

HbA1c and blood glucose: These help determine whether the current treatment plan is achieving the person’s individualized glucose targets.

Cardiovascular and kidney health: A history of cardiovascular disease, heart failure or chronic kidney disease can influence which medicines are appropriate.

Body weight: Some medicines can support weight reduction, while others may contribute to weight gain.

Hypoglycemia risk: Medicines such as insulin and sulfonylureas can increase the risk of low blood glucose, particularly when used alongside other glucose-lowering treatments.

Kidney function: Some medicines require dose adjustments or may not be suitable when kidney function is reduced.

Adverse effects: Persistent or troublesome side effects may influence whether a particular medicine is appropriate.

Cost, availability and preferences: Affordability, access, convenience and individual preferences should also be considered.

The 2026 ADA standards of care recommend that treatment should be individualized and a shared decision-making approach should be used.

Common Medicines Used Alongside Metformin

There are several different classes of drugs available for people with diabetes. Each will work in a slightly different way and have varying effects on blood sugar levels and possible side effects.

This gives an idea of what may be considered but is not a hierarchy or recommendation for a specific patient.

Metformin and SGLT2 Inhibitors

SGLT2 inhibitors increase the amount of glucose removed through the urine by the kidneys.

Examples include dapagliflozin, empagliflozin and canagliflozin.

SGLT2 inhibitors can be used alongside metformin to give additional glucose-lowering effects. Certain medicines in this class have demonstrated benefits in people with heart failure and chronic kidney disease.

Potential side effects include genital fungal infections and volume depletion. In some cases SGLT2 inhibitors can cause diabetic ketoacidosis. This can occur even when glucose levels are not very high.

Factors to consider include kidney function, medical history and other medications.

Metformin and GLP-1-Based Medicines

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It acts on two incretin hormone pathways and can provide substantial glucose-lowering and weight-management effects.

It may be considered alongside metformin for some people with type 2 diabetes, depending on their treatment goals, medical history and individual circumstances.

Common adverse effects include nausea, vomiting, diarrhoea and other gastrointestinal symptoms. Its suitability and possible benefits should be discussed with a healthcare professional.

GLP-1 Receptor Agonists

GLP-1 receptor agonists act via incretin hormone mechanisms.

These medicines increase insulin release in response to elevated blood glucose, reduce glucagon secretion, slow stomach emptying to varying degrees and influence appetite.

Examples include semaglutide, dulaglutide and liraglutide.

A suitable GLP-1 receptor agonist can provide further glucose lowering if prescribed with metformin. Certain medicines in this class have demonstrated cardiovascular benefits and can support weight management in appropriate patients.

Side effects such as nausea, vomiting, diarrhea and other gastrointestinal symptoms can occur. The chance of side effects will depend on the individual.

These drugs may be of particular relevance if weight management or cardiovascular risk is an important consideration.

Metformin and DPP-4 Inhibitors

DPP-4 inhibitors slow the breakdown of incretin hormones. This helps support glucose-dependent insulin release and reduce glucagon secretion.

Examples include sitagliptin and linagliptin.

DPP-4 inhibitors should generally not be used alongside GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists because the combination does not provide meaningful additional glucose-lowering benefits.

The risk of hypoglycemia may increase when DPP-4 inhibitors are used alongside insulin or sulfonylureas. A healthcare professional may need to review the doses of these medicines.

Metformin and Sulfonylureas

Sulfonylureas stimulate the pancreas to release more insulin. Examples include glimepiride and glipizide.

These medicines may be used alongside metformin in selected people, including when affordability and access influence treatment decisions. However, hypoglycemia and weight gain are important risks that must be considered.

Those prescribed a sulfonylurea should know the signs of low blood sugar levels and follow the advice of their health care professional.

Metformin and Pioglitazone

Pioglitazone is a thiazolidinedione drug that increases the sensitivity of the body to insulin.

It may be used in combination with metformin in some people with type 2 diabetes.

Important limitations include weight gain, fluid retention (Edema), an increased risk of heart failure in susceptible individuals and a higher risk of fractures. These risks need to be considered carefully before pioglitazone is prescribed.

Metformin and Insulin

Insulin may be prescribed alongside metformin when additional glucose control is required or when blood glucose levels are particularly high.

The 2026 ADA Standards of Care recommend considering insulin when people have symptoms of hyperglycemia or very high blood glucose levels, such as an HbA1c above 10% or blood glucose levels of 300 mg/dL or higher.

For people without severe hyperglycemia or a hyperglycemic crisis, GLP-1-based treatment is generally preferred to insulin as an initial or add-on glucose-lowering option.

The need for insulin and the appropriate treatment plan should be assessed by a healthcare professional. Insulin can increase the risk of hypoglycemia, so monitoring and medication adjustments may be necessary.

What Is Metformin Triple Therapy?

Metformin triple therapy involves using metformin together with two additional glucose-lowering medicines.

This may be considered if dual therapy isn’t providing adequate control of glucose levels, or if further drugs are required to manage certain risks.

The medicines selected depend on the individual’s health conditions, treatment goals, previous response to medication and potential adverse effects.

A clinician may select metformin together with an SGLT2 inhibitor and a DPP-4 inhibitor in selected circumstances. Other treatment plans may involve a GLP-1 receptor agonist, tirzepatide or insulin, depending on the patient’s medical needs and response to treatment.

Some combinations are not recommended. For example, DPP-4 inhibitors should generally not be combined with GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists because there is no meaningful additional glucose-lowering benefit.

There is no universal HbA1c threshold that automatically means someone should start triple therapy. The clinician must consider the patient’s response to existing treatment, side effects, interactions, kidney function, treatment burden and individual targets.

Are Fixed-Dose Metformin Combinations an Option?

There are combination preparations of some diabetes medications containing two or more active ingredients in one tablet.

Examples include metformin and an SGLT2 inhibitor or DPP-4 inhibitor. Certain markets also have fixed-dose tablets containing three diabetes medicines, although availability and suitability vary by country.

This may reduce the number of tablets that need to be taken, making management of treatment easier.

However, fixed-dose combinations are not suitable for everyone. The doses of both medicines must be appropriate, and the formulation must fit the person’s kidney function, medical history and treatment needs.

If the dose of one ingredient needs to change, a fixed-dose combination may be less convenient because the amounts of both medicines are fixed together.

How Is Combination Therapy Started and Monitored?

Starting combination therapy is a medical decision. Do not add another diabetes medicine, stop a prescribed medicine or change a dose without advice from your healthcare professional.

Combination therapy will usually involve:

Assessing how well your diabetes has been controlled

This could involve looking into your recent HbA1c levels, blood sugar levels, current medications and any symptoms/side effects.

Review metformin adherence and tolerability

Your healthcare professional may check whether you are taking metformin as prescribed and whether the current dose and formulation are well tolerated.

If there are issues with gastrointestinal side effects, a change to the formulation or current treatment may be considered.

Our guide to taking extended-release metformin correctly provides more information about this formulation.

Other health conditions and renal function

Other factors that may affect the choice of medication include renal function, cardiovascular disease, heart failure, weight and other health conditions.

Your doctor should also review all prescription medicines, over-the-counter medicines, vitamins, herbal products and dietary supplements you are taking, as some may interact with diabetes medicines.

Choosing the right medication

Medication should be chosen based on your treatment targets, anticipated benefits, safety, cost and personal preferences.

Your doctor will advise you on how to take your medication and which symptoms or side effects should be reported.

Follow-up

Your blood sugar levels, HbA1c and relevant safety tests may be monitored.

The ADA recommends assessing glycemic status at least twice a year. More frequent assessment, such as every three months, may be appropriate when treatment goals are not being met, after recent treatment changes, or when glucose levels are unstable.

Side Effects and Safety Considerations

Combination therapy can improve blood glucose control, but using multiple medicines may also increase the risk of adverse effects or drug interactions.

Metformin – common side effects include diarrhea, nausea, stomach discomfort and bloating. It can contribute to vitamin B12 deficiency in some individuals if taken long term.

SGLT2 inhibitors – Possible side effects include genital fungal infections, dehydration/volume depletion and diabetic ketoacidosis.

GLP-1 receptor agonists – Can cause gastrointestinal side effects such as nausea, vomiting and diarrhea.

DPP-4 inhibitors – Generally well tolerated, although some people may experience upper respiratory symptoms, headache or other adverse effects. Refer to the prescribing information for the specific medicine for less common but important safety warnings.

Sulfonylureas – Hypoglycemia and weight gain are important risks.

Pioglitazone – May cause weight gain and fluid retention and can increase the risk of heart failure in susceptible people. Fracture risk is another important consideration.

When a new diabetes medicine is started, the clinician should review whether the dose of an existing medicine with a higher risk of hypoglycemia, such as insulin or a sulfonylurea, needs to be reduced or adjusted.

Severe hypoglycemia can cause confusion, seizures or loss of consciousness and requires urgent medical attention.

Frequently Asked Questions:

When is another medicine added to metformin?

Another drug may be considered if someone is not able to achieve their target glucose levels despite following an appropriate management strategy. It may also be considered earlier if their HbA1c is markedly increased or if there are cardiovascular, heart failure or kidney related considerations.

Do I need combination therapy for my type 2 diabetes?

Not everyone will require combination therapy. Some individuals will be able to achieve their treatment targets with only one drug while others will require multiple drugs. This will depend on individuals’ specific glucose targets, medical problems and how well they respond to treatment.

Can I take two drugs for my diabetes?

Yes, some people with type 2 diabetes may need two medicines, either from the beginning of treatment or when additional glucose control is needed. The 2026 ADA Standards of Care recommend considering initial combination therapy to help achieve individual glucose targets sooner. This decision should be made with a healthcare professional.

What is the best drug to combine with metformin?

There is no single best medicine to combine with metformin for everyone. The choice depends on individual glucose targets, cardiovascular and kidney health, weight goals, hypoglycemia risk, affordability and personal preferences.

Can I take an SGLT2 inhibitor with metformin?

This can be done. It is a well-established treatment for some individuals with type 2 diabetes. Some SGLT2 inhibitors have been shown to have benefits for the heart and kidneys. This will depend on kidney function, medical history and drug selected.

Can I take a GLP-1 receptor agonist with metformin?

Yes. A GLP-1 receptor agonist may be prescribed to be used alongside metformin if further glucose control or treatment benefits are required. This will depend on the drug and treatment.

Some people may also be considered for tirzepatide, a dual GIP/GLP-1 receptor agonist, although its suitability and availability depend on individual circumstances and local prescribing guidance.

Can I take a DPP-4 inhibitor with a GLP-1 receptor agonist?

This combination is generally not recommended. Using a DPP-4 inhibitor with a GLP-1 receptor agonist or a dual GIP/GLP-1 receptor agonist does not provide meaningful additional glucose-lowering benefits. The 2026 ADA Standards of Care advise against these combinations.

If two drugs aren’t working, will I always need three drugs?

Not necessarily. A clinician will review the treatment and determine if a third drug, alternative combination, injection or other change would be appropriate.

Are combination tablets better?

Combination tablets can make taking medication easier by reducing the number of tablets taken. However they will not be suitable for everyone. Doses, kidney function, tolerability, cost and treatment requirements should be considered.

Can I take supplements instead of another drug for my diabetes?

Dietary supplements should not be used as an alternative to prescribed diabetes treatment. Some supplements may also interact with prescribed drugs. Speak to a healthcare professional about taking any supplements.

Key Takeaway

Metformin combination therapy can help people with type 2 diabetes achieve their individual treatment goals when one medicine alone is insufficient or when another medicine offers additional health benefits.

Treatment options include SGLT2 inhibitors, GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, DPP-4 inhibitors, sulfonylureas, pioglitazone and insulin. Each option has different benefits, limitations and potential side effects.

Using more medicines is not automatically better. The most appropriate treatment should consider blood glucose targets, cardiovascular and kidney health, weight goals, hypoglycemia risk, affordability and personal preferences.

Discuss treatment changes with your healthcare professional. Never start, stop or combine diabetes medicines without appropriate medical advice.

References

Learn More About Our Standards

Treatment recommendations can vary between countries. NICE guidance reflects clinical practice in the United Kingdom, while other countries may follow different national guidelines and prescribing recommendations. Patients should follow the advice of their local healthcare professionals.

admin

All Posts